LEXINGTON, Ky. — University of Kentucky Markey Cancer Center researchers identified a protein important in prostate cancer progression and resistance to enzalutamide, a common prostate cancer treatment.
Drugs targeting this protein – casein kinase 1 alpha (CK1α) – could reverse enzalutamide resistance and improve outcomes for patients with prostate cancer, according to the study published in Cell Reports Medicine on April 18.
Prostate cancer is the most common cancer and the second-leading cause of cancer mortality among men in the U.S., largely due to the development of therapy resistance during treatment.
Drugs like enzalutamide, which inhibit male hormones from activating the androgen receptor, have been a mainstay of care in treating advanced prostate cancer. However, metastatic prostate cancers can develop resistance to enzalutamide and there is limited understanding of how this occurs.
“Our lab is the first to report the role of CK1α in prostate cancer progression and enzalutamide resistance,” said Jinghui Liu, Ph.D., the study’s lead author and assistant professor in the UK College of Medicine’s Department of Toxicology and Cancer Biology.
“What’s most exciting is that our findings have a very high potential to translate to clinical research and be immediately beneficial to patients with enzalutamide-resistant prostate cancer,” said Liu, who is a researcher in the lab of Xiaoqi Liu, Ph.D., the chair of the department of Toxicology and Cancer Biology and Lucille P. Markey Endowed Chair in Oncology Research.
The study paves the way for the launch of a clinical trial utilizing a combination of a CK1α inhibitor called BTX-A51 with enzalutamide to treat late-stage prostate cancer. The Food and Drug Administration has already approved BTX-A51 for its use in a clinical trial on acute myeloid leukemia.
Liu’s team used a CRISPR-Cas9 knockout screen to identify CK1α as a top therapeutic target. The study validates this finding using several preclinical models that show inhibiting CK1α greatly improves the effectiveness of enzalutamide.
The study also highlights how CK1α is linked to enzalutamide resistance. The team found that CK1α modifies a protein called ataxia telangiectasia mutated (ATM) using RNA sequencing and mass spectrometry analysis. ATM initiates DNA damage response signaling, which is compromised in enzalutamide resistance.
With this understanding, ATM could also be utilized as a prognostic biomarker to predict the clinical outcome of enzalutamide.